November 9, 2022 MedinCell announces its participation in the Jefferies London Healthcare Conference 2022, 15-17 November in London Read press release
November 7, 2022 MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement Read press release
November 3, 2022 MedinCell’s partner Teva today announced refiling for approval of mdc-IRM and confirmed planned launch in the U.S. in H1 2023 Read press release
September 14, 2022 MedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission Read press release
September 13, 2022 MedinCell releases the results of its September 8, 2022 ordinary annual and extraordinary general meeting Read press release
September 5, 2022 MedinCell secures additional 20 million euros financing with the European Investment Bank (EIB) Read press release
